David Gaiero - Nov 20, 2023 Form 4 Insider Report for Cyteir Therapeutics, Inc. (CYT)

Role
Chief Financial Officer
Signature
/s/ David Gaiero
Stock symbol
CYT
Transactions as of
Nov 20, 2023
Transactions value $
$124,433
Form type
4
Date filed
11/22/2023, 01:47 PM
Previous filing
Feb 7, 2023
Next filing
Dec 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CYT Common Stock Options Exercise $88.3K +52.6K +372.94% $1.68 66.7K Nov 20, 2023 Direct
transaction CYT Common Stock Options Exercise $36.1K +21.4K +32.03% $1.69 88K Nov 20, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CYT Stock Option (Right to Buy) Options Exercise $0 -52.6K -71.41% $0.00 21.1K Nov 20, 2023 Common Stock 52.6K $1.68 Direct F2
transaction CYT Stock Option (Right to Buy) Options Exercise $0 -21.4K -18.75% $0.00 92.5K Nov 20, 2023 Common Stock 21.4K $1.69 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 5,000 shares of the Company's common stock pursuant to the Cyteir Therapeutics, Inc. Employee Stock Purchase Program ("ESPP"). In accordance with the ESPP, these shares were purchased based on 85% of the closing stock price on January 17, 2023.
F2 The option vested as to 25% of the underlying shares of common stock on December 7, 2021, the first anniversary of the vesting commencement date, and vests as to 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.
F3 The option vests as to 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.